ArticleFrontiers in neurology2025
Expression profile of long noncoding RNAs in post-stroke aphasia.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Post-stroke aphasia (PSA) is one of the most common complications after stroke, seriously affecting survivors' quality of life. While long noncoding RNAs (lncRNAs) are linked to stroke, their role in PSA remains unclear. This study explored PSA-associated lncRNA expression to identify potential biomarkers. Methods: LncRNA expression profiles were analyzed via high-throughput RNA sequencing (RNA-seq) with subsequent quantitative polymerase chain reaction (qPCR) validation. Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment, and correlations with language behaviors were assessed. Results: Initial analyses comparing PSA and stroke patients revealed 797 significantly differentially expressed lncRNAs (69 upregulated, 728 downregulated), linked to several metabolic pathways. qPCR confirmed upregulation of lncRNA RP11-227G15.3 in PSA. A negative correlation with oral spelling scores was observed in 12 PSA patients ( Conclusion: This is an exploratory pilot study. LncRNA RP11-227G15.3 represents a candidate biomarker requiring validation for PSA, though its preliminary association with oral spelling scores requires validation in larger, independent cohorts before any clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.